ArticleCell communication and signaling : CCS2026
Epothilone B stabilizes microtubules via Tau to protect retinal ganglion cells and promote axon regeneration.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAs the structural framework and conduit for axonal material transport, microtubule stability plays a crucial role in the repair of optic nerve injury. Tau maintains the integrity of these transport tracks by promoting microtubule bundling. However, injury-induced aberrant phosphorylation of Tau markedly impairs its microtubule-binding capacity, leading to microtubule disassembly and eventual neurodegeneration. This study investigated Tau-mediated regulation of microtubule homeostasis and explored its potential application in axonal repair and regeneration following optic nerve injury.
methodsUsing molecular docking and molecular dynamics simulations, we identified epothilone B (EpoB) as a microtubule-stabilizing compound and systematically characterized its interaction mechanisms with the tubulin-Tau complex. Two mouse retinal ganglion cell (RGC) axonal injury models, retinal ischemia-reperfusion (I/R) and optic nerve crush (ONC), were established to evaluate neuroprotective effects through adeno-associated virus-mCherry axonal labeling and electron microscopy. Comprehensive assessments integrating anterograde and retrograde axon tracing (CTB/Fluoro-gold) and visual electrophysiology elucidated the regulatory mechanisms of microtubule stabilization on axonal protection and regeneration.
resultsMolecular dynamics simulations revealed that EpoB stabilizes the binding interface between Tau and tubulin via hydrogen bonding and hydrophobic interactions, significantly reducing the binding free energy (ΔGbind difference of 15.8 kcal mol− 1) and enhancing the affinity between tubulin and Tau. In mouse models of RGC injury, retinal I/R and ONC, EpoB treatment significantly inhibited abnormal phosphorylation at Tau Thr231/Ser262/Ser396 sites and reduced the formation of retraction bulbs by more than 50%. It preserved the ordered microtubule structure within axonal retraction bulbs, enhanced anterograde and retrograde transport functions, maintained long-distance axonal projections, and protected RGCs. Furthermore, EpoB can maintain microtubule stability in growth cones, producing an additive improvement in promoting axonal regeneration of optic nerves when combined with PTEN knockdown.
conclusionThis study reveals a novel mechanism by which EpoB stabilizes microtubules via Tau and presents a strategy for promoting axonal repair and regeneration by stabilizing microtubules, providing a new perspective for treating diseases associated with optic nerve injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.